OTCMKTS:HKMPFHikma Pharmaceuticals Stock Price, Forecast & News

$30.50

0.00 (0.00 %)

(As of 05/28/2020 04:00 PM ET)

Add

Compare

Today's Range

$30.50

Now: $30.50▼

$30.50

50-Day Range

$26.90

MA: $29.32▼

$32.00

52-Week Range

$19.75

Now: $30.50▼

$32.00

Volume212 shs

Average Volume560 shs

Market Capitalization$7.39 billion

P/E Ratio20.33

Dividend YieldN/A

Beta0.44

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals. The Generics segment develops and sells oral and other non-injectable generic products for retail market. The Branded segment develops, manufactures, and markets branded generics and in-licensed products to retail and hospital markets. The company offers products in various therapeutic areas, including respiratory, oncology, pain management, anti-infectives, cardiovascular, diabetes, and central nervous system. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Hikma Pharmaceuticals.

2.2 Community Rank

Outperform Votes
Hikma Pharmaceuticals has received 117 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Hikma Pharmaceuticals has received 152 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Hikma Pharmaceuticals has received 56.51% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote “Outperform” if you believe HKMPF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HKMPF will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Hikma Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Hikma Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hikma Pharmaceuticals insiders have not sold or bought any company stock.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Hikma Pharmaceuticals are expected to grow by 14.10% in the coming year, from $1.56 to $1.78 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Hikma Pharmaceuticals is 20.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.99.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hikma Pharmaceuticals is 20.33, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.43.
Price to Book Value per Share Ratio
Hikma Pharmaceuticals has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.69 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Private households

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:HKMPF

Previous SymbolOTC:HKMPF

CUSIPN/A

CIKN/A

Webwww.hikma.com

Phone44-20-7399-2760

Debt

Debt-to-Equity Ratio0.05

Current Ratio1.26

Quick Ratio0.87

Price-To-Earnings

Trailing P/E Ratio20.33

Forward P/E Ratio19.55

P/E GrowthN/A

Sales & Book Value

Annual Sales$2.21 billion

Price / Sales3.35

Cash Flow$1.87 per share

Price / Cash Flow16.28

Book Value$8.79 per share

Price / Book3.47

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees8,600

Outstanding Shares242,320,000

Market Cap$7.39 billion

Next Earnings Date5/28/2020 (Estimated)

OptionableNot Optionable

Receive HKMPF News and Ratings via Email

Sign-up to receive the latest news and ratings for HKMPF and its competitors with MarketBeat's FREE daily newsletter.

Hikma Pharmaceuticals (OTCMKTS:HKMPF) Frequently Asked Questions

How has Hikma Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Hikma Pharmaceuticals' stock was trading at $24.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HKMPF stock has increased by 24.5% and is now trading at $30.50. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Hikma Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Hikma Pharmaceuticals.

When is Hikma Pharmaceuticals' next earnings date?

Hikma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 28th 2020. View our earnings forecast for Hikma Pharmaceuticals.

Has Hikma Pharmaceuticals been receiving favorable news coverage?

Media headlines about HKMPF stock have trended somewhat positive this week, InfoTrie reports. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Hikma Pharmaceuticals earned a news impact score of 1.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutHikma Pharmaceuticals.

Who are some of Hikma Pharmaceuticals' key competitors?

Some companies that are related to Hikma Pharmaceuticals include SEVEN & I HOLDI/ADR (SVNDY), DENSO CORP/ADR (DNZOY), ESSILOR INTL S/S (ESLOY), CK HUTCHISON HO/ADR (CKHUY), COMPASS GRP PLC/S (CMPGY), AMADEUS IT HLDG/ADR (AMADY), CHINA CITIC BK/ADR (CHCJY), UNICHARM CORP/S (UNICY), HENNES & MAURIT/ADR (HNNMY), KERRY GRP PLC/S (KRYAY), Eisai (ESALY), SWIRE PAC LTD/S (SWRAY), A P MOLLER-MAER/ADR (AMKBY), ASSA ABLOY AB/S (ASAZY) and FERROVIAL S A/ADR (FRRVY). View all competitors.

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the following people:

Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 62)
Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 61)
Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 50)
Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 47)
Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPF."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Hikma Pharmaceuticals' stock price today?

One share of HKMPF stock can currently be purchased for approximately $30.50.

How big of a company is Hikma Pharmaceuticals?

Hikma Pharmaceuticals has a market capitalization of $7.39 billion and generates $2.21 billion in revenue each year. The company earns $486 million in net income (profit) each year or $1.50 on an earnings per share basis. Hikma Pharmaceuticals employs 8,600 workers across the globe.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is www.hikma.com.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The company can be reached via phone at 44-20-7399-2760 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff